Aller au contenu

Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study.

Nom du journal : Haematologica

Année : 2023

Volume : 108

Page de départ : 2774-2782

Auteurs: Talbot, A, Bobin, A, Tabone, L, Lambert, J, Boccaccio, C, Deal, C & al,